Strategies for improving outcomes in NSCLC: A look to the future

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 375-382

  Stahel, Rolf ^a   Peters, Solange ^b   Baas, Paul ^c   Brambilla, Elisabeth ^d   Cappuzzo, Federico ^e   De Ruysscher, Dirk ^f   Eberhardt, Wilfried Ernst Erich ^g   Felip, Enriqueta ^h   Fennell, Dean ⁱ   Marchetti, Antonio ^j   Paz Ares, Luis ^k   Adjei, Alex A ^l  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d HÔPITAL MICHALLON   (France)

^e ISTITUTO TOSCANO TUMORI   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j UNIVERSITY OF CHIETI   (Italy)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Biomarkers; Clinical trials; Lung cancer; Management; Molecular profiling; Outcomes; Pathogenesis; Treatment

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AMG 888; ANTINEOPLASTIC AGENT; CABOZANTINIB; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CONATUMUMAB; DACOMITINIB; DROZITUMAB; FIGITUMUMAB; FORETINIB; GANETESPIB; GANITUMAB; GEMCITABINE; IMGATUZUMAB; INIPARIB; LINSITINIB; MAPATUMUMAB; MM 121; OLAPARIB; PALBOCICLIB; PICTILISIB; R 1507; RETASPIMYCIN; RILOTUMUMAB; ROSCOVITINE; TIGATUZUMAB; TIVANTINIB; U 3 1287; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; XL 147; XL 228; XL 765;

CANCER RADIOTHERAPY; CANCER SURVIVAL; EUROPE; HEALTH SERVICE; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADICAL RESECTION; REVIEW; SURVIVAL RATE;

BIOMARKERS; CLINICAL TRIALS; LUNG CANCER; MANAGEMENT; MOLECULAR PROFILING; OUTCOMES; PATHOGENESIS; TREATMENT;

ANIMALS; BIOMEDICAL RESEARCH; CARCINOMA, NON-SMALL-CELL LUNG; EUROPE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGNOSIS; QUALITY IMPROVEMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84887618347     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.025     Document Type: Review

References (94)

1. Cancer Research UK 2012 Lung Cancer 2012, http://www.cancerresearchuk.org/cancer-info/print/%20?files=CRUKMIG_100019758,CRUKMIG_100019760,CRUKMIG_100019763,CRUKMIG_100019761,CRUKMIG_100019764,CRUKMIG_100019762,CRUKMIG_100019759&parentfile=CRUKMIG_100019764#source17.
2. De Angelis R., Francisci S., Baili P., Marchesi F., Roazzi P., Belot A., et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009, 45:909-930.
3. Petersen I. The morphological and molecular diagnosis of lung cancer. Dtsch Arztebl Int 2011, 108:525-531.
4. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
5. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
6. Travis W.D. NCI Directors challenge gene profiling of lung adenocarcinomas: impact on histologic classification. J Thoracic Oncol 2004, 2:S254-S256.
7. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma. Proc Am Thorac Soc 2011, 8:381-385.
8. Thunnissen E., Kerr K.M., Herth F.J., Lantuejoul S., Papotti M., Rintoul R.C., et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012, 76:1-18.
9. Bergman P., Brodin D., Lewensohn R., de Petris L. Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases. Acta Oncol 2012, (Epub ahead of print).
10. Travis W.D., Brambilla E., Riely G. New pathological classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
11. Yoshizawa A., Motoi N., Rieley G., Sima C.S., Gerald W.L., Kris M.G., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
12. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
13. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
14. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
15. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
16. National Comprehensive Cancer Network Non-small Cell Lung Cancer. Version 2 2012, http://www.nccn.com/patient-guidelines.html.
17. Gerber D. EGFR Inhibition in the treatment of non-small cell lung cancer. Drug Dev Res 2008, 69:359-372.
18. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
19. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
20. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
21. Rosell R., Massuti Sureda B., Costa C., Molina M.A., Gimenez-Capitan A., Karachaliou N. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3). Presented at the ESMO 2012 Congress, September 28-October 2 2012, abstr LBA31.
22. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
23. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
24. Tiseo M., Gelsomino F., Bartolotti M., Bordi P., Bersanelli M., Rossi G., et al. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2011, 11:1677-1687.
25. Ma P., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65:1479-1488.
26. Paik P., Arcila M., Fara M., Sima C., Miller V., Kris M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
27. Kawano O., Sasaki H., Endo K., Suzuki E., Haneda H., Yukiue H., et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54:209-215.
28. Ise N., Omi K., Nambara D., Higashiyama S., Goishi K. Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors. Anticancer Res 2011, 31:4155-4161.
29. Jun H.J., Johnson H., Bronson R.T., de Feraudy S., White F., Charest A. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 2012, 72:3764-3774.
30. Mano Y., Takahashi K., Ishikawa N., Takano A., Yasui W., Inai K., et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007, 98:1902-1913.
31. Marchetti A., Milella M., Felicioni L., Cappuzzo F., Irtelli L., Del Grammastro M., et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role of mutations in minor clones. Neoplasia 2009, 11:1084-1092.
32. Shigematsu H., Gazdar A. Somatic mutations of epidermal growth factor signalling pathway in lung cancers. Int J Cancer 2006, 118:257-262.
33. Stahel R., Thatcher N., Früh M., Le Péchoux C., Postmus P.E., Sorensen J.B., et al. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011, 22:1973-1980.
34. Kamal N.S., Soria J.C., Mendiboure J., Planchard D., Olaussen K.A., Rousseau V., et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16:1206-1215.
35. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii56-vii64.
36. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., et al. FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7:348-354.
37. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008, 15:241-247.
38. Sholl L.M., Xiao Y., Joshi V., Yeap B.Y., Cioffredi L.A., Jackman D.M., et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010, 133:922-934.
39. Eberhard D.A., Giaccone G., Johnson B.E., Non-Small-Cell Lung Cancer Working Group Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-994.
40. Hirsch F.R., Wynes M.W., Gandara D.R., Bunn P.A. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010, 16:4909-4911.
41. Ross J., Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011, 136:527-539.
42. Marchetti A., Del Grammastro M., Filice G., Felicioni L., Rossi G., Graziano P., et al. Complex mutations and subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 2012, 7:e42164.
43. Buttitta F., Felicioni L., Del Grammastro M., Filice G., Di Lorito A., Malatesta S., et al. Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next generation sequencing. Clin Cancer Res 2013, 19:691-698.
44. Voelkerding K., Dames S., Durtschi J. Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009, 55:641-658.
45. Felip E., Gridelli C., Baas P., Rosell R., Stahel R., Panel Members Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011, 22:1507-1519.
46. Crinò L., Weder W., van Meerbeeck J., Felip E., On behalf of the ESMO Guidelines Working Group Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v103-v115.
47. Sak A., Stuschke M., Groneberg M., Kübler D., Pöttgen C., Eberhardt W.E. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys 2012, 84:492-499.
48. Ricciardi S., Tomao S., de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag 2009, 5:781-787.
49. Dy G.K., Hillman S.L., Rowland K.M., Molina J.R., Steen P.D., Wender D.B., et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010, 116:5686-5693.
50. Dragnev K.H., Petty W.J., Shah S.J., Lewis L.D., Black C.C., Memoli V., et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 2007, 13:1794-1800.
51. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., Minken A., Wanders R., Lutgens L., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006, 24:1057-1063.
52. Mauguen A., Le Péchoux C., Saunders M.I., Schild S.E., Turrisi A.T., Baumann M., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012, 30:2788-2797.
53. Aerts H.J., van Baardwijk A.A., Petit S.F., Offermann C., Loon Jv Houben R., Dingemans A.M., et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009, 91:386-392.
54. van Elmpt W., De Ruysscher D., van der Salm A., Lakeman A., van der Stoep J., Emans D., et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012, 104:67-71.
55. Koh P.K., Faivre-Finn C., Blackhall F.H., De Ruysscher D. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev 2012, 38:626-640.
56. van Elmpt W., Ollers M., Dingemans A.M., Lambin P., De Ruysscher D. Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med 2012, 53:1514-1520.
57. Simon G., Sharma A., Li X., Walsh F., Williams C., Chiappori A., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
58. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17:1160-1168.
59. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368:1101-1110.
60. Lovly C.M., Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012, 4:120ps2.
61. Chen Z.Y., Zhong W.Z., Zhang X.C., Su J., Yang X.N., Chen Z.H., et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012, 17:978-985.
62. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.
63. Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., et al. an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
64. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
65. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
66. Oxnard G., Lo P., Jackman D., Butaney M., Heon S., Johnson B., et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. J Clin Oncol 2012, 30(Suppl.). abstr 7547.
67. Faehling M., Eckert R., Kamp T., Kuom S., Griese U., Sträter J., et al. Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. J Clin Oncol 2012, 30(Suppl.). abstr 7572.
68. Janjigian Y., Smit E.F., Horn L., Groen H., Camidge D., Gettinger S., et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Presented at the ESMO 2012 Congress, September 28-October 2 2012, abstr 1227O.
69. Goldberg S., Oxnard G., Digumarthy S., Muzikansky A., Jackman D., Lennes I., et al. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol 2012, 30(Suppl.). abstr 7524.
70. Mok T., Lee J., Zhang L., Yu C., Thongprasert S., Ladrera G., et al. Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2012, 23(Suppl. 9). abstr 12260.
71. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
72. Ross H.J., Blumenschein G.R., Aisner J., Damjanov N., Dowlati A., Garst J., et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010, 16:1938-1949.
73. Arteaga C.L. HER3 and mutant EGFR meet MET. Nat Med 2007, 13:675-677.
74. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
75. Janne P., Shaw A., Pereira J., Jeannin G., Vansteenkiste J., Barrios C., et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30(Suppl. 15):7503.
76. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
77. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
78. Topalian S., Brahmer J., Hodi F., McDermott D., Smith D., Gettinger S., et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker for response. J Clin Oncol 2012, 30(Suppl.). abstr CRA2509.
79. EurocanPlatform. Available at:. http://eurocanplatform.eu/.
80. European Oncology Thoracic Platform. Available at:. http://www.etop-eu.org/.
81. O'Connor S. Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe. Eur J Cancer 2011, 47(Suppl. 3):S346-S347.
82. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22:777-784.
83. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22:785-794.
84. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
85. Maione P., Gridelli C., Troiani T., Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006, 11:274-284.
86. Camidge D., Bang Y., Kwak E., Shaw A., Iafrate A., Maki R., et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). abstr 2501.
87. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
88. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
89. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
90. Douillard J.Y., Rosell R., DeLena M., Carpagnano F., Ramlau R., Gonzáles-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stageIB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
91. Cancer Research UK 2012 Lung cancer survival statistics 2012, http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/lung-cancer-survival-statistics#Trends.
92. Gondos A., Holleczek B., Arndt V., Stegmaier C., Ziegler H., Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?. Ann Oncol 2007, 18:1253-1259.
93. Brooks D., Klint A., Dickman P., Stahle E., Lambe M. Temporal trends in non-small cell lung cancer survival in Sweden. Br J Cancer 2007, 96:519-522.
94. Verdecchia A., Guzzinati S., Francisci S., De Angelis R., Bray F., Allemani C., et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009, 45:1042-1066.